Mounjaro hits shelves in India: How Eli Lilly’s anti-diabetes drug compares with Ozempic — price, side effects and more

Eli Lilly has introduced Mounjaro (tirzepatide), a weekly injectable medication for obesity and type 2 diabetes, in India after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels. While Ozempic is often…

Read More
Back To Top